Libmeldy, the one-off gene therapy for children with a rare, life-limiting neurodegenerative disorder, will be made available on the National Health Service in England after Orchard Therapeutics dropped the price it was asking for what is reportedly the world’s most expensive drug.
The NHS said that Libmeldy (atidarsagene autotemcel) would be offered as treatment for metachromatic leukodystrophy (MLD) after it negotiated “a...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?